# HD17 for Intermediate Stage Hodgkin Lymphoma

> **NCT01356680** · PHASE3 · COMPLETED · sponsor: **University of Cologne** · enrollment: 1100 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)
- **DRUG:** ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
- **RADIATION:** 30Gy IF-RT (Involved-Field Radiotherapy)
- **RADIATION:** 30Gy IN-RT (Involved-Node Radiotherapy)

## Key facts

- **NCT ID:** NCT01356680
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-13
- **Primary completion:** 2020-03-21
- **Final completion:** 2020-03-23
- **Target enrollment:** 1100 (ACTUAL)
- **Last updated:** 2020-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356680, "HD17 for Intermediate Stage Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01356680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*